MECHANISMS IN ENDOCRINOLOGY

The sexually dimorphic role of androgens in human metabolic disease

Lina Schiffer¹, Punith Kempegowda¹, Wiebke Arlt¹² and Michael W O’Reilly¹²

¹Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham, UK and
²Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, University Hospitals Birmingham
NHS Foundation Trust, Edgbaston, Birmingham, UK

Abstract

Female androgen excess and male androgen deficiency manifest with an overlapping adverse metabolic phenotype, including abdominal obesity, insulin resistance, type 2 diabetes mellitus, non-alcoholic fatty liver disease and an increased risk of cardiovascular disease. Here, we review the impact of androgens on metabolic target tissues in an attempt to unravel the complex mechanistic links with metabolic dysfunction; we also evaluate clinical studies examining the associations between metabolic disease and disorders of androgen metabolism in men and women. We conceptualise that an equilibrium between androgen effects on adipose tissue and skeletal muscle underpins the metabolic phenotype observed in female androgen excess and male androgen deficiency. Androgens induce adipose tissue dysfunction, with effects on lipid metabolism, insulin resistance and fat mass expansion, while anabolic effects on skeletal muscle may confer metabolic benefits. We hypothesise that serum androgen concentrations observed in female androgen excess and male hypogonadism are metabolically disadvantageous, promoting adipose and liver lipid accumulation, central fat mass expansion and insulin resistance.

Introduction

Disturbances in androgen metabolism secondary to gonadal, adrenal or hypothalamic–pituitary disease lead to alterations of circulating androgen concentrations, and result in reproductive and metabolic complications. In women, polycystic ovary syndrome (PCOS), a triad of ovulatory dysfunction, polycystic ovarian morphology and androgen excess (AE), represents the most common endocrine disorder (1). In men, disturbances of gonadal function most commonly result in hypogonadism and consequent androgen deficiency (AD), which can be inherited or acquired by disease, obesity, medications or the ageing process (2). Interestingly, female AE and male AD are associated with a similar adverse metabolic phenotype, including obesity, insulin resistance (IR), an increased prevalence of type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD) and even premature mortality (3,4,5,6,7,8). This highlights a sexual dimorphism in the relationship between androgens and metabolism. As serum testosterone (T) concentrations in female AE and male AD may overlap, Escobar-Morreale et al. have proposed the concept of a metabolically adverse window of circulating androgen concentrations that are associated with deleterious metabolic consequences (9), or a ‘metabolic valley of death’ (Fig. 1). However, the cellular and systemic mechanisms underpinning these phenomena are poorly understood. In this article, we will discuss disorders of AE in women and AD in men, examine the role of androgens in the function of metabolic target tissues, and compare phenotype and consequences of metabolic dysfunction in the context of AE and AD.
Androgens in metabolic disease

Androgens are 19-carbon (C19) steroid hormones produced by the adrenal gland and gonads in both men and women; they derive from C21 precursor steroids and can be converted to C18 steroids, the oestrogens. The androgen precursor steroids dehydroepiandrosterone (DHEA) and androstenedione (A4) are secreted mainly by the adrenal glands in both sexes, and by the ovary in females. Active T is produced directly in testicular Leydig cells in men and ovarian theca cells in women, but may also be activated from precursors in peripheral tissues (10), and can be generated in small amounts by the adrenal gland (10). T can be converted downstream to the more potent androgen 5α-dihydrotestosterone (DHT) by 5α-reductase activity. T and DHT bind and activate the androgen receptor (AR), eliciting classic genomic androgen action.

Androgens can be synthesised from cholesterol via three interconnected pathways, which are schematically visualised in Fig. 2. The classical pathway produces T, which is activated to DHT in peripheral target tissues. There are several alternative pathways to DHT synthesis that bypass the classic synthesis pathway; the so-called backdoor pathway (11, 12, 13) and alternate 5α-dione pathway (14, 15) that directly synthesise DHT by-passing T. In healthy men, circulating T concentrations are approximately 10-fold higher than those observed in women (16). Besides de novo biosynthesis, active androgens can be synthesised from circulating androgen precursors in peripheral tissues expressing the required enzymes, thereby modulating local androgen exposure. In adipose tissue, A4 is converted to T by 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5), also called as aldoketoreductase type 1C3 (AKR1C3), and T may be further activated to DHT by the type 1 isoform of 5α-reductase (17).

Recently, it has been shown that steroids downstream of the major adrenal androgen precursor 11β-hydroxyandrostenedione (11OHA4), generated from A4 via the adrenal CYP11B1 enzyme (18), are active 11-oxygenated androgens (19). 11-keto-testosterone (11KT) and 11-keto-5α-dihydrotestosterone (11KDHT) (Fig. 2) have been shown to have the same AR activating potential as T and DHT, both with regard to affinity and transactivation potential (20), raising the possibility of an important role for these previously overlooked androgens in conveying biological androgen action (21). While all four agonists have comparable maximum transactivation potential for the AR, DHT and 11KDHT also have an AR affinity that is approximately one order of magnitude higher than the affinity of T and 11KT highlighting the importance of peripheral 5α-reductase activity for androgen action (21). Importantly, the circulating levels of 11KT have been shown to be approximately four times higher than those of T in healthy premenopausal women, which demonstrates the significant contribution of 11-oxygenated androgens

---

**Pre-receptor androgen synthesis and metabolism**

Androgens can be synthesised from cholesterol via three interconnected pathways, which are schematically visualised in Fig. 2. The classical pathway produces T, which is activated to DHT in peripheral target tissues. There are several alternative pathways to DHT synthesis that bypass the classic synthesis pathway; the so-called backdoor pathway (11, 12, 13) and alternate 5α-dione pathway (14, 15) that directly synthesise DHT by-passing T. In healthy men, circulating T concentrations are approximately 10-fold higher than those observed in women (16). Besides de novo biosynthesis, active androgens can be synthesised from circulating androgen precursors in peripheral tissues expressing the required enzymes, thereby modulating local androgen exposure. In adipose tissue, A4 is converted to T by 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5), also called as aldoketoreductase type 1C3 (AKR1C3), and T may be further activated to DHT by the type 1 isoform of 5α-reductase (17).

Recently, it has been shown that steroids downstream of the major adrenal androgen precursor 11β-hydroxyandrostenedione (11OHA4), generated from A4 via the adrenal CYP11B1 enzyme (18), are active 11-oxygenated androgens (19). 11-keto-testosterone (11KT) and 11-keto-5α-dihydrotestosterone (11KDHT) (Fig. 2) have been shown to have the same AR activating potential as T and DHT, both with regard to affinity and transactivation potential (20), raising the possibility of an important role for these previously overlooked androgens in conveying biological androgen action (21). While all four agonists have comparable maximum transactivation potential for the AR, DHT and 11KDHT also have an AR affinity that is approximately one order of magnitude higher than the affinity of T and 11KT highlighting the importance of peripheral 5α-reductase activity for androgen action (21). Importantly, the circulating levels of 11KT have been shown to be approximately four times higher than those of T in healthy premenopausal women, which demonstrates the significant contribution of 11-oxygenated androgens
Androgens in metabolic disease

L Schiffer and others

Androgen excess in women and related metabolic consequences

Polycystic ovary syndrome

PCOS is the most common cause of AE in women, affecting 5–10% of women of reproductive age (4, 23). PCOS is diagnosed according to the 2003 Rotterdam criteria (24), with two of the following three features required for diagnosis: ultrasound appearance of polycystic ovarian morphology (PCO), anovulation (AO) and AE. However, PCOS is also a major metabolic disorder, associated with IR, visceral adiposity and obesity, dyslipidaemia, NAFLD, CVD and potentially premature mortality (3, 4). PCOS-associated metabolic dysfunction is intimately linked with AE (25) (Fig. 1). Conventionally, circulating androgen burden has been typically evaluated by measuring serum T (25, 26), but recent work has defined A4 as a more sensitive marker for detecting PCOS-related AE, as well as demonstrating that integrated assessment of A4 and T is predictive of adverse metabolic risk (22, 27). Increased circulating concentrations of the DHEA sulfate ester DHEAS and 11OHA4, as well as active 11-oxygenated androgens, are indicative of AE of adrenal origin in PCOS. The latter was explored for the first time in a recent study, which demonstrated that more than half of the circulating androgen pool in a large cohort of PCOS women consisted of 11-oxygenated androgens (22), highlighting the significant adrenal contribution to PCOS-related AE. Of note, this increase in circulating 11-oxygenated androgens was similarly observed in...
obese and non-obese PCOS women, raising the question whether androgen excess precedes the development of metabolic complications.

In addition to systemic AE, tissue-specific androgen activation and its dysregulation contribute to local androgen burden. Systemic upregulation of 5α-reductase activity is observed in PCOS (28, 29, 30); resulting in enhanced activation of T to DHT; this phenomenon is already observed in daughters of PCOS women in early childhood (31). However, it is controversial whether daughters of PCOS women also develop a metabolic and biochemical phenotype and ovarian morphology characteristic of PCOS during puberty (32, 33). Overexpression of the steroidogenic enzyme AKR1C3 in PCOS adipose tissue is likely to contribute to tissue-specific AE, as this is the only enzyme expressed in adipose tissue that can locally generate T from A4 via its 17βHSD activity (34). AKR1C3 expression is increased in adipose tissue from patients with simple obesity and decreases with weight loss (34); furthermore, AKR1C3 expression in adipose tissue from PCOS patients is higher than in body mass index (BMI)-matched controls (35). Weight loss has been shown to represent an effective treatment to ameliorate PCOS-associated AE, ovulatory dysfunction and metabolic issues (36), further supporting an important role for adipose tissue as an organ of androgen generation in PCOS.

Women with monogenic causes of androgen excess

The variants of congenital adrenal hyperplasia (CAH) represent a group of inborn disorders with autosomal recessive inheritance characterized by glucocorticoid deficiency and variable impact on mineralocorticoid and androgen secretion. Three CAH variants are associated with AE in affected women: 21-hydroxylase deficiency, 11β-hydroxylase deficiency and 3β-hydroxysteroid dehydrogenase type 2 deficiency. The most common defect is 21-hydroxylase deficiency, with a frequency of 1:16000 in newborns (37, 38) and is the only enzyme deficiency frequently resulting in a non-classic CAH form with only mild glucocorticoid deficiency, but relevant AE (39, 40). As a consequence of the enzymatic block, precursor steroids are shunted down the pathways of androgen biosynthesis, which is further increased by enhanced hypothalamic–pituitary adrenal drive due to the loss of the negative feedback by cortisol (18, 41). While patients with major loss-of-function mutations usually present at birth or in early childhood, patients with mild mutations are often only diagnosed in early adulthood, as their glucocorticoid and mineralocorticoid secretion is sufficiently upheld by continuously increased ACTH stimulation of the adrenals, at the expense of AE. These patients usually do not present with outright virilisation, but generally with a PCOS phenotype in adolescence or early adulthood, including hirsutism, irregular periods and PCO appearance of the ovaries. In patients with non-classic CAH, an increased prevalence of obesity and insulin resistance has been reported (42, 43, 44), mirroring the adverse metabolic phenotype found in PCOS. As PCOS represents a diagnosis of exclusion and on average 2–3% of women presenting with a PCOS phenotype are identified as suffering from non-classic CAH (4), screening for CAH by baseline serum 17-hydroxyprogesterone is recommended in the work-up of PCOS.

Recently, another monogenic cause of AE, PAPSS2 deficiency (PAPSS2, 3′-phophoadenosine 5′-phosphosulfate synthase 2), has been described to present with a PCOS-like phenotype (45). PAPS is the universal sulfate donor, generated by the two human PAPS synthase isoforms, and inactivating mutations in PAPS synthase 2 have been shown to result in significantly impaired DHEA sulfotransferase (SULT2A1) activity (46). Consequently, fewer molecules of the androgen precursor DHEA are inactivated to DHEAS, resulting in increasing rates of conversion of DHEA towards T and DHT (Fig. 2). The first reported case, a homozygously affected young girl, presented with premature pubarche followed by irregular cycles and secondary amenorrhoea; investigations revealed AE with non-detectable serum DHEAS. Interestingly, her heterozygous mother, who harboured a major loss-of-function mutation on one allele, had presented with PCOS as a young woman (45). A further family affected by PAPSS2 deficiency was recently identified, and work-up revealed significant AE not only in the affected children but also in the heterozygous mother, co-incidentally again the carrier of a major loss-of-function mutation, with clinical manifestation as PCOS (47).

Women with monogenic insulin resistance

Severe insulin resistance can develop independent of obesity as a consequence of monogenic gene defects impacting on insulin signalling or adipose tissue development. Defects in insulin signalling can be found at the level of the insulin receptor or in post-receptor signal transduction. Monogenic disorders may also cause severe obesity and consequent IR, or dysfunctional adipose tissue development resulting in congenital complete
or partial lipodystrophy (48). Patients with IR due to monogenic lipodystrophy or insulin receptor (INSR) mutations present with AE, ovulatory dysfunction, PCO and acanthosis nigricans, usually in the absence of obesity. Compensatory hyperinsulinaemia may stimulate ovarian androgen biosynthesis by direct effects of insulin on theca and stromal cells (49), although other peripheral sources of insulin-stimulated androgen generation cannot be discounted. Monogenic INSR mutations may be suspected clinically in the setting of severe hyperinsulinaemia, which is accompanied by normal or elevated levels of leptin, adiponectin and SHBG, alongside a normal lipid profile and absence of hepatic steatosis (48).

**Androgen deficiency in men and related metabolic consequences**

Male AD is a clinical syndrome arising from failure of testicular T production, in the context of primary testicular pathology or hypothalamic–pituitary disease (2). In adult men, it is diagnosed by the presence of physical symptoms of AD with biochemical evidence of low circulating T. Common symptoms are a reduction of libido and erectile strength, fatigue, reduced physical strength and endurance as well as sometimes impaired cognitive function and mood disturbances (50).

**Primary male hypogonadism**

Primary male hypogonadism (HG) is defined by low serum T in combination with increased luteinizing hormone (LH). Normal T and high LH levels characterize compensated hypogonadism, which represents impaired testicular function that is rescued by increased LH stimulation. Compensated hypogonadism is subclinical, but increases the likelihood to progress to overt AD when compared to the eugonadal state (51). Congenital primary HG can be caused by gonadal dysgenesis and cryptorchidism (52), as well as by autosomal or sex chromosome aneuploidies like in Klinefelter syndrome (53, 54).

**Secondary male hypogonadism**

Secondary HG, or hypogonadotropic HG, is defined by low T and reduced gonadotrophin secretion due to impaired hypothalamic–pituitary stimulation of testicular androgen synthesis. The overwhelming majority of such cases are caused by tumours of the hypothalmo–pituitary area. Congenital hypogonadotropic hypogonadism may be observed in the context of multiple pituitary hormone deficiencies in conditions such as septo-optic dysplasia, but more commonly is associated with isolated gonadotrophin deficiency as observed in Kallmann syndrome, which may be associated with anosmia and cranio-facial abnormalities (55).

**Acquired male hypogonadism**

Acquired HG may be caused by lesions or tumours of the central nervous system or testis, radio- and chemotherapy, pharmacological treatment, chronic illness, poor health and obesity (2). Surgical or pharmacological androgen deprivation therapy is an established treatment option for both metastatic hormone-naive and castration-resistant prostate cancer (56).

Ageing affects the hypothalamic–pituitary–gonadal (HPG) axis and can lead to late-onset AD, which is defined as low T levels if any form of classical causes of AD can be excluded (57). Ageing can result in gradual development of testicular failure due to a decreased number and response to LH of Leydig cells, and in reduced hypothalamic–pituitary signalling (58, 59). This manifests in an age-related decline of T levels of around 0.1 nmol/L per year starting during the third decade of life (60).

Male AD can also be induced by obesity (61). Obesity significantly increases the age-related T decline and is associated with disordered gonadotrophin release (60). Conversely, weight loss can reverse obesity-associated hypogonadism (62). The concept of a hypogonadal–obesity–adipokine cycle is a proposed mechanism behind this association (50, 63, 64): Obesity has been suggested to lead to enhanced aromatisation of androgens to oestrogens by aromatase (CYP19A1, Fig. 2) in adipose tissue, thereby reducing the level of active androgens. Oestrogens may suppress the HPG axis, which reduces gonadal T synthesis (65). Treatment of obese men with the CYP19A1 inhibitor letrozole normalises T levels (66). Additionally, elevated levels of adipocyte-derived inflammatory cytokines (67, 68) have been shown to inhibit the HPG axis in healthy men and a contribution of leptin excess to the reduction of androgens in obesity has been suggested (69).

**Androgens and metabolic health in transgender patients**

Replacement and blockade of sex hormones underpin the principle of gender reassignment, both before and after gonadectomy where appropriate, thereby enabling
the development of secondary sex characteristics of the desired gender. Circulating sex hormones should be maintained in the upper-normal physiological reference range for the desired gender (70, 71). However, metabolic consequences for androgen deprivation and replacement therapy may be observed in both male-to-female and female-to-male gender reassignment patients (72).

**Female-to-male gender reassignment**

For female-to-male gender reassignment, T is administered both before and after genital reconstruction surgery, aiming to induce virilisation and suppress female secondary sex characteristics. Target serum T levels are generally between 12 and 24 nmol/L (70). Long-term T administration for female-to-male gender transition increases total lean mass (73) and visceral fat mass, while reducing subcutaneous fat mass (74); BMI may be increased (75, 76). Surrogate cardiovascular risk factors have been reported to be increased by T administration, including arterial stiffness, blood pressure (77) and dyslipidaemia (78). Female-to-male transgender patients also show an increased prevalence of T2DM compared to female control populations (79, 80). Despite presenting with PCOS symptoms, female-to-male transgender patients taking T show ovarian hyperplasia, but no polycystic ovarian morphology (81) further supporting that AE and not ovarian dysfunction drives the metabolic phenotype in PCOS.

**Male-to-female gender reassignment**

Oral or transdermal oestrogen supplementation is the primary treatment for feminization of male-to-female transgender patients, both before and after orchidectomy; anti-androgen treatment is frequently co-prescribed in the pre-gonadectomy stage (71). Serum T levels <1.9 nM are recommended (71). Delineating the specific effects of androgen deprivation therapy in this patient population is clouded by co-administration of relatively large doses of oestrogen. Male-to-female transgender patients on combined estrogen and anti-androgen treatment develop an adverse lipid profile (76, 78) with reduced muscle mass and total lean mass percentage, but increased subcutaneous and visceral fat mass (73, 74). Prevalence rates of T2DM, thrombo-embolic disease and cerebrovascular disease compared to control men appear to be increased (79).

**The role of androgens in metabolic target tissues**

In addition to their central role in the development and maintenance of male and female reproduction and sex drive, androgens exert key effects on metabolic target tissues. These include adipose tissue and skeletal muscle, compartments crucially involved in maintaining systemic glucose and lipid homeostasis.

**Androgens, adipose tissue and lipid metabolism**

There is a clear sexual dimorphism in patterns of body fat distribution, with women having a higher percentage of body fat than men, while men have greater total lean mass. In women, body fat is distributed in a gynaecoid manner, with less visceral but more subcutaneous (SC) fat; men have a predominant android fat distribution, with more visceral and less SC adipose tissue (82, 83, 84). Adipose tissue expansion is a consequence of both hyperplasia (adipogenesis), which is driven by proliferation of preadipocytes and their differentiation into adipocytes, and hypertrophy, which is driven by accumulation of lipid in differentiated adipocytes; both processes are major determinants of metabolic dysfunction (85).

Androgens impair adipogenesis by inhibiting proliferation and differentiation of mesenchymal stem cells and preadipocytes (86). DHT and T have inhibitory effects on multipotent stem cell commitment to the preadipocyte lineage, and adipocyte differentiation in both sexes (87, 88). In addition, DHEA, but not DHEAS, has been shown to inhibit proliferation and differentiation of a human SC preadipocyte cell line and to enhance basal glucose uptake (89). Klötting et al. hypothesise that an impairment of adipocyte proliferation and differentiation may lead to adipocyte hypertrophy as a compensatory mechanism to increase adipose tissue mass, which could induce adipocyte dysfunction manifested in IR, intracellular stress and inflammation (90).

Hypertrophic, dysfunctional adipocytes induce a proinflammatory, diabetogenic and atherogenic serum profile (90). However, comprehensive human in vivo studies evaluating the direct effects of androgens on the secretion of cytokines by adipose tissue are lacking. Incubation with active androgens in primary cultures of human abdominal SC and omental adipocytes from male and female donors (88) showed no significant effect on adiponectin secretion, which has systemic insulin-sensitizing effects. However, women with PCOS
have lower levels of adiponectin than healthy controls (91), and hypogonadal men show higher adiponectin than eugonadal men (92) suggesting a potential role for androgens in adiponectin secretion.

Androgens may modulate the balance between lipid catabolism and lipid accumulation. However, studies to date have shown conflicting results. T and its precursor DHEAS have been shown to stimulate lipolysis in humans in a sex- and depot-specific manner (93, 94, 95, 96, 97). Conversely, Corton et al. have compared the expression profile of omental adipocytes in obese women with AE to the profile of obese controls with normal androgens revealing hints at enhanced lipogenesis (98, 99) and thus at a possible role of androgens in promoting adipose lipid accumulation.

Androgens also exert direct and indirect effects on adipose insulin sensitivity. T directly induces IR in female SC adipocytes in vitro, and inhibits insulin-stimulated glucose uptake by impairing phosphorylation of protein kinase C via an AR-mediated mechanism (100). The adipose gene expression studies by Corton et al. comparing adipocytes from women with and without PCOS show distinct changes in several biological pathways, including oxidative stress, inflammation and lipid metabolism (98). Effects of androgens on adipose tissue are summarised in Fig. 3.

**Androgens, skeletal muscle and insulin sensitivity**

Androgens enhance the differentiation of stem cells to myotubes, as well as skeletal muscle protein synthesis, lipid oxidation, insulin sensitivity and glucose usage and mitochondrial function (64, 101) (Fig. 3). The intake of T in combination with non-aromatisable synthetic androgens increases the number of myonuclei, resulting from fusion with satellite cells and promoting muscular growth, and proportion of central nuclei indicative of muscle repair in human skeletal muscle of athletes compared to non-steroid users (102). T stimulates the proliferation and differentiation of satellite cells (103), which can subsequently fuse with the adjacent myofiber. Additionally, androgens induce myogenic differentiation and inhibit adipogenesis of pluripotent mesenchymal stem cells via an AR-dependent pathway (104). Healthy men receiving intramuscular T injections exhibit increases in skeletal muscle protein synthesis (105). Intramuscular T replacement in hypogonadal men confirms the effect of T in reducing protein oxidation (106). In men, T correlates with genetic and functional markers of mitochondrial function in skeletal muscle (107), consistent with findings reporting a positive effect of T on mitochondrial biogenesis and maintenance in skeletal muscle of mice (108, 109).

Incubation of primary human muscle cells with T leads to an upregulation of insulin receptor substrate-2 (110). In cultured rat muscle cells, the addition of T and DHEA enhances GLUT4 expression and translocation to the plasma membrane as well as intracellular insulin signalling (111). T and DHEA stimulate the activity of phosphofructokinase, the key regulatory enzyme of glycolysis, and hexokinase, which phosphorylates free glucose, thereby impairing its release from the cell and channelling it into the pathways of glycolysis, glycogen synthesis or the pentose phosphate pathway (111). T administration leads to increases in muscle glycogen levels in rat (112) due to reduced glycogen breakdown (113). In summary, current evidence suggests that androgens stimulate insulin sensitivity and glucose utilisation in skeletal muscle cells, in both men and women but with sex-specific gradual differences, hinting at a stronger effect in females (110).
Table 1  Selected studies highlighting the effects of androgens on metabolic dysfunction in men and women.

| Metabolic outcomes/Sex | Study design | Parameters assessed: Main outcome | Reference |
|-----------------------|-------------|-----------------------------------|-----------|
| Body composition      |             |                                   |           |
| M                     | 139 PCOS grouped according to combination of PCO, AO and AE | BMI: No difference  <br> WHR: ↑ in groups with AE, highest in PCO + AO + AE | (135)     |
| M                     | 60 PCOS (biochemical and/or clinical AE) vs 60 controls matched for age, race, BMI | WHR: ↑ in PCOS  <br>% body fat: ↑ in PCOS  <br>Lean mass: No difference  <br>Fat–lean–mass ratio: ↑ in PCOS | (131)     |
| F                     | 130 nonsmoking men, age 21–70 | Body fat mass, % body fat, WC, vic adiposity: Negatively associated with T and DHEAS | (121)     |
| M/F                   | 17 female-to-male transsexuals on T supplementation followed over 1 year | T levels: ↑ to supraphysiol levels  <br>Body fat distribution: ↓ SC, ↑ vis fat  <br>TG: ↑  <br>HDL: ↓ | (206)     |
| IR and T2DM           |             |                                   |           |
| M                     | 86 PCOS grouped according to severity of AE vs 43 controls (matched for age and BMI) | T and A4, IGT, fasting insulin, HOMA-IR: ↑ with severity of AE | (25)      |
| M                     | 15 PCOS on resveratrol treatment vs 15 PCOS placebo controls | T, DHEAS: ↓ by resveratrol  <br>Fasting insulin: ↓ by resveratrol  <br>ISI: ↑ by resveratrol | (119)     |
| F                     | 1413 men, age ≥20 | T levels, Prevalence of diabetes: Negative association: Free T, bioavailable T and diabetes persisting upon exclusion of men with abnormally low T | (207)     |
| F                     | 156 obese, hypogonadal, diabetic men on T therapy followed over 6 years | Fasting insulin, glycate Hb, WC, weight, blood pressure: ↓  <br>Lipid profile: Ameliorated | (128)     |
| NAFLD                 |             |                                   |           |
| M                     | Prospective cross-sectional study involving 314 PCOS women and 74 controls | Various liver fibrosis scores, HOMA-IR, HOMA-β, QUICKI: Indices of hepatic steatosis were all significantly higher in the PCOS than the control group, as well as in PCOS women with rather than without metabolic syndrome | (151)     |
| M                     | Prospective case control study with 29 PCOS women and 29 controls | HOMA-IR, MRI liver, MRS: Differences in liver fat remained apparent after adjusting for differences in obesity and insulin resistance | (152)     |
| F                     | Retrospective cross-sectional observation study of 495 healthy Korean men | Serum testosterone, BMI, HDL, TG: Low serum T was associated with higher risk of NAFLD independent of vis fat and IR | (154)     |
| F                     | Prospective cohort study of 55 men with chronic spinal cord injury | Serum T, ultrasonography liver, HOMA-IR: Low T was independently associated with NAFLD | (208)     |
| F                     | Cross-sectional population-based study of 1912 men | Serum T, serum DHEAS, ultrasonography liver: Hepatic steatosis was associated with low T and high DHEAS | (155)     |
| Dyslipidaemia and CVR |             |                                   |           |
| M                     | PCOS on hypocaloric diet and flutamide or placebo treatment | A4, DHEAS: ↓ secondary to flutamide  <br>Vis/SC fat TG, cholesterol, LDL: ↓  <br>HDL: Trend for ↑ | (141)     |
| M                     | 40 PCOS vs 20 normoandrogenic controls | CIMT: ↑ in PCOS; Correlation with total T, free T, A4 and DHEAS | (164)     |
| M                     | 2301 PCOS (evidence of AE in 88%) followed over 20 years | T2DM, MI, angina, HF, stroke, CV related death: ↑ age-specific prevalence of T2DM, MI, angina compared to local male population | (172)     |
Insulin resistance, type 2 diabetes mellitus and androgen status in men and women

Insulin resistance is defined as the impaired systemic metabolic response to insulin, which includes glucose uptake and metabolism, suppression of lipolysis and promotion of lipogenesis, as well as protein and glycogen synthesis (114). IR is accompanied by compensatory hyperinsulinemia, leading to an exaggerated insulin response in normally less responsive tissues, as well as disturbances in hepatic and adipose lipid metabolism. Frank hyperglycaemia occurs after decompensation of the exaggerated pancreatic beta-cell response to systemic insulin resistance. Studies selected from those discussed in the following sections are summarised in Table 1.

Female androgen excess and insulin resistance

The presence of AE in PCOS is closely correlated with insulin resistance. Women with PCOS show a trend to progress from normal glucose tolerance to impaired glucose tolerance (IGT) and to T2DM, and obesity significantly increases this risk (115). Both obese and non-obese PCOS women with AE show a higher prevalence of IGT and T2DM than controls, but obesity deteriorates the diabetic phenotype (116, 117). Conversely, T levels are significantly higher in women with T2DM even after adjustment for age, race, diabetes diagnosis criteria, BMI and waist-to-hip ratio; consequently, AE in women has been suggested as risk factor for T2DM (118). When grouping PCOS patients according to severity of AE, insulin sensitivity decreases and risk of overt hyperglycaemia increases across a spectrum or increasing androgen burden (25). Lowering circulating androgen burden in PCOS by treatment with resveratrol has been shown to reduce fasting insulin and to improve the insulin sensitivity index (119). In vitro studies demonstrated selective inhibition of proliferation and androgen production of rat ovarian theca-interstitial cells by resveratrol (120).

Male androgen deficiency and insulin resistance

In men, T levels are positively associated with insulin sensitivity (107, 121) and even in men with an established diagnosis of T2DM, low T is independently associated with IR (122). A meta-analysis correlating significantly lower T levels in men with T2DM also found the inverse association in women, with higher T levels predicting hyperglycaemia (118). The significance of this correlation is attenuated, but still significant, after adjustment for IR (123, 124). An increase in the prevalence of subnormal T has been found in diabetic men when compared to BMI-matched controls (125). This identifies low T levels as a risk factor for T2DM, independent of obesity. Men with prostate cancer on androgen deprivation therapy have higher BMI, fasting glucose, leptin levels and HOMA-IR compared to healthy controls, with significant negative correlations between total and free T and IR parameters observed (126). Androgen replacement therapy improves insulin sensitivity and diabetes in obese and non-obese hypogonadal men (127, 128).

Table 1

| Metabolic outcomes/Sex | Study design | Parameters assessed: Main outcome | Reference |
|------------------------|-------------|-----------------------------------|-----------|
| F                      | 255 hypogonadal men receiving T therapy for 60 months | T levels: ↑ to physiological levels TG, LDL, blood pressure, glucose, glycated HbA, CRP, liver enzymes: ↓ HDL: ↑ | (209) |
| F                      | 4736 men with low T supplemented to persistently low, normal or high T for 3 years | MACE (stroke, MI, death): ↓ in normal T compared to persistently low T; ↑ stroke risk for high T compared to normal T | (198) |

A4, androstenedione; BMI, body mass index; CIMT, carotid intima-media thickness; CRP, C-reactive protein; CV, cardiovascular; CVR, cardiovascular risk; DHEA, dehydroepiandrosterone; DHEAS, dihydroepiandrosterone sulfate; HbA, haemoglobin A; HDL, high density lipoprotein; HF, heart failure; HOMA-β, homeostatic model assessment of β-cell function; HOMA-IR, homeostatic model assessment of insulin resistance; IR, insulin resistance; ISI, insulin sensitivity index; LDL, low density lipoprotein; MACE, major adverse cardiovascular event; MI, myocardial infarct; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; QUICKI, quantitative insulin sensitivity check index; Ref, reference; SC, subcutaneous; T, testosterone; T2DM, type 2 diabetes mellitus; TG, triglycerids; vis, visceral; WC, waist circumference; WHR, waist–hip ratio.
Body composition and impact of androgen status in men and women

Similar to the gender-specific effects observed for androgen effects on systemic IR, there are sexually dimorphic effects of androgens on body composition.

Female androgen excess and body composition

PCOS women with clinical and/or biochemical evidence of AE show a higher prevalence of obesity than the general female population (4) and an increased global adiposity compared to control cohorts (129). In a detailed study comparing hyperandrogenic PCOS women, healthy women and men, Borruel et al. demonstrated increased amounts of visceral fat depots in women with PCOS in addition to the increased global adiposity (130). They have an increased body fat mass resulting in a higher body fat-to-lean mass ratio, which is positively associated with metabolic risk (131, 132). For women with and without PCOS, BMI correlates with the FAI and systemic 5α-reductase activity (25) and body weight, waist circumference and waist-to-hip ratio are higher in the presence of AE in PCOS (133, 134, 135). Women presenting with isolated hirsutism show significantly higher increases in BMI during early adulthood than controls (136). A recent study found a significant positive correlation between circulating androgens with body fat mass and obesity in pre-pubertal and pubertal girls (137).

Studies on PCOS women with AE describe an increased lean mass correlating with serum T and A4 (138, 139), with a shift in fat distribution from a gynaecoid to an android pattern (132). The treatment of PCOS women on a hypocaloric diet with the anti-androgen flutamide decreases androgen levels and the visceral-to-SC fat ratio (140, 141).

Male androgen deficiency and body composition

In comparison to women, circulating androgens in men correlate inversely with BMI and visceral adiposity. Cross-sectional studies analysing age-advanced men, men across different ages and obese vs non-obese men consistently support the association between low T and increased fat mass compared to eugonadal controls (107, 142, 143). BMI negatively correlates with total and free T (142, 144), and waist circumference is negatively associated with total T in men (142). Although age is associated with decreased androgen levels (143, 144), negative associations between T and total body fat mass, body fat percentage, waist circumference and visceral adipose tissue are maintained after adjustment for age (121). T administration in men reduces accumulation of visceral and retroperitoneal fat compared to controls, but not in SC depots; hypogonadal men also have increased visceral fat mass (145). Lean body mass is lower in hypogonadal men compared to eugonadal controls (146, 147). T replacement therapy of hypogonadal men leads to increases in lean body mass and reduces vis adiposity in men with and without T2DM (127, 148).

Non-alcoholic fatty liver disease (NAFLD) and male and female androgen status

NAFLD is an umbrella term encompassing a spectrum of hepatic injury induced by obesity and IR, in the absence of significant alcohol consumption. The NAFLD spectrum ranges from intra-hepatic accumulation of TG or simple steatosis, to diffuse tissue inflammation or non-alcoholic steato-hepatitis (NASH), with a risk of progression to advanced hepatic fibrosis and cirrhosis (149). NAFLD is a major metabolic complications and emerging as the most frequent cause of liver transplantation in the Western world.

Female androgen excess and NAFLD

Prevalence rates of NAFLD in PCOS appear to be higher than those in BMI-matched individuals from the background population; a recent meta-analysis found that patients with PCOS have an almost 4-fold higher prevalence of NAFLD compared to controls with simple obesity (150). Polyzos and colleagues reported a significantly higher prevalence of hepatic steatosis in a large cohort of Mediterranean women with PCOS when compared to the healthy female population. However, they did not find any difference in the prevalence of hepatic fibrosis, which was attributed to younger age of the cohort (151). Jones et al. compared several metabolic parameters in PCOS women with and without AE diagnosed according to the Rotterdam criteria and found that liver fat was significantly higher in hyperandrogenic PCOS compared to normoandrogenic PCOS women (diagnosed with PCOS due to PCO+AO), even after adjustment for obesity, IR and visceral and intra-abdominal fat (152). Androgenised female rats fed with a diet rich in advanced glycation end products have been shown to develop deranged hepatic function (153). However, putative causative mechanisms underlying PCOS-related NAFLD remain to be elucidated.
Male androgen deficiency and NAFLD

Kim et al. report that low serum T level was independently associated with NAFLD in Korean men despite adjusting for traditional risk factors such as visceral adiposity and IR (154). A large observational study of German men also reported an inverse association between serum T and hepatic steatosis (155). Although indirect mechanisms, such as increased visceral adiposity in the context of hypogonadism, were initially hypothesised, recent studies have underpinned a direct role for androgens on liver metabolism. Liver-specific male AR knock-out mice develop hepatic steatosis and IR with a high fat diet. This appears to be due to activation and upregulation of sterol regulatory element binding protein-1c and acetyl coA carboxylase, coupled with a reduction in peroxisome proliferator-activated receptor-alpha and malonyl coA decarboxylase expression. This results in increased malonyl co-A, a substrate for de novo lipogenesis and negative regulator of carnitine palmitoyltransferase 1, which is a major regulator of beta-oxidation (156). Mirroring female AE, however, excessive androgen replacement and supraphysiological serum androgens may also adversely impact on risk of NAFLD in men. Synthetic anabolic steroid use has been linked to hepatic steatosis in men (157), again suggesting the presence of a relatively narrow physiological window outside of which adverse metabolic consequences may arise.

Cardiovascular risk and male and female androgen status

Female androgen excess and cardiovascular risk

According to a recent meta-analysis, AE in PCOS is associated with higher total cholesterol and lower HDL levels, but does not affect TG and LDL levels (158). Studying the direct associations between AE and dyslipidaemia is confounded by co-existent obesity and IR in most PCOS studies. Nevertheless, treatment with the anti-androgen flutamide improves the dyslipidaemic phenotype in both obese and non-obese women and leads to decreases in T and A4 levels probably secondary to normalisation of ovulation and gonadotrophin secretion (140, 141, 159). Despite large inter-study heterogeneity, profiles of circulating markers for systemic inflammation, oxidative stress and coagulation disorders appear to be altered in PCOS, indicating an increased CVR (91, 160, 161, 162, 163).

Lueque-Ramirez et al. comparing hyperandrogenic PCOS with non-hyperandrogenic women showed an increased mean carotid intimal media thickness (CIMT) in PCOS, independent of obesity, and identified total T and A4 as major determinants of CIMT (164). Women with PCOS and AE also exhibit microvascular dysfunction due to impaired vasodilation (165, 166). Data on long-term cardiovascular events in PCOS are inconsistent. Some studies conclude that there is no increased risk for large vessel disease (167), abdominal aortic plaque (168), myocardial infarction (MI) or stroke (169, 170). Others describe increases in the prevalence of hypertension (168, 170) and cerebrovascular disease (171), in the age-specific prevalence of MI and angina (172) and in the risk of coronary heart disease and stroke, even after adjustment for BMI (173). General and cause-specific mortality and age at death may not be significantly higher in PCOS women than the background population (167, 169, 170, 174).

Male androgen deficiency and cardiovascular risk

In men, low T levels are associated with a dyslipidaemic profile. An inverse relation between T and TG, total cholesterol and LDL as well as a positive correlation of total and free T with HDL (175, 176, 177, 178, 179, 180) was described. ADT for the treatment of PCa also induces dyslipidaemia (181, 182, 183), while T replacement therapy in hypogonadal men exhibits beneficial effects on the lipid profile (127, 184, 185). An inverse correlation exists between serum T and high-sensitive C-reactive protein in normal ageing (186) and hypogonadal (187) men, and T replacement has been shown to shift the cytokine balance towards a state of reduced inflammation (184, 188).

Increased arterial stiffness has been reported in hypogonadal men compared to age- and weight-matched controls, which can be rapidly but incompletely rescued by T supplementation (189). Men with coronary artery disease present with lower T levels (190, 191) and its severity is negatively correlated with T levels (190, 192, 193). Male AD is associated with a higher risk of all-cause mortality (194, 195), and an inverse correlation exists between T levels and prospective mortality due to all causes, cardiovascular disease and cancer (196). We found that men with gonadotrophin deficiency after the treatment of non-functioning pituitary adenomas had increased mortality compared to their eugonadal counterparts (197). Supplementing men with initially low T levels to normal T levels reduces the rate of stroke, MI or death compared to subjects with persistently low T (198, 199).
Conclusions

Androgens play a major role in human metabolic health and disease. Female androgen excess and male androgen deficiency exhibit overlapping metabolic phenotypes, highlighting the complexity of the role of androgens in metabolism (Fig. 1). Effects of androgens on adipose tissue and muscle may largely be governed by circulating serum and tissue-specific concentrations, with a narrow physiological window in both sexes, outside of which disturbances in metabolism and body composition are observed. In healthy women, low androgen concentrations and elevated oestrogens lead to predominant gynaecoid fat distribution and reduced metabolic risk; at circulating androgen levels observed in severe female AE and male AD, preferential accumulation of central and visceral adiposity is observed, while at higher androgen concentrations seen in healthy men, this effect is dissipated by increasing lean body mass, muscle bulk and reducing fat mass (Fig. 3). Further human-based studies, including in vitro, in vivo and epidemiological studies appropriately taking into account sex differences, are required to understand and dissect these complex associations.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work was supported by the Wellcome Trust (Clinical Research Training Fellowship 099909, to M O R, and Project Grant 092283, to W A).

References

1 Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Frank S, Gambineri A, Kelestemur F, Macul D, Micic D, Pasquali R et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. European Journal of Endocrinology 2014 171 P1–P29. (doi:10.1530/EJE-14-0253)
2 Bhasin S & Basaria S. Diagnosis and treatment of hypogonadism in men. Best Practice and Research Clinical Endocrinology and Metabolism 2011 25 251–270. (doi:10.1016/j.beem.2010.12.002)
3 Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocrine Reviews 2003 24 302–312. (doi:10.1210/er.2003-0004)
4 Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES & Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 2004 89 2745–2749. (doi:10.1210/jc.2003-032046)
5 Corona G, Vignozzi L, Sforza A, Mannucci E & Maggi M. Obesity and late-onset hypogonadism. Molecular and Cellular Endocrinology 2015 418 120–133. (doi:10.1016/j.mce.2015.06.031)
6 Zarotsky V, Huang MY, Carman W, Morgentaler A, Singhal PK, Coffin D & Jones TH. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2014 2 819–834. (doi:10.1111/andr.274)
7 Mintziori G, Poulakos I, Tsametsi C & Goulios DG. Hypogonadism and non-alcoholic fatty liver disease. Minerva Endocrinologica 2017 42 145–150. (doi:10.23736/S0391-1977.16.02570)
8 Corona G, Rastelli G, Monami M, Gaay A, Buvat J, Sforza A, Forti G, Mannucci E & Maggi M. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology 2011 165 687–701. (doi:10.1530/EJE-11-0447)
9 Escobar-Morreale HF, Alvarez-Blasco F, Botella-Carretero JJ & Luque-Ramirez M. The striking similarities in the metabolic associations of female androgen excess and male androgen deficiency. Human Reproduction 2014 29 2083–2091. (doi:10.1093/humrep/deu198)
10 Rege J, Nakamura Y, Satoh F, Morimoto R, Kennedy MR, Layman LC, Homma S, Sasano H & Rainey WE. Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. Journal of Clinical Endocrinology and Metabolism 2013 98 1182–1188. (doi:10.1210/jc.2012-2912)
11 Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Haufpa BP, Malunowicz EM et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004 363 2128–2135. (doi:10.1016/S0140-6736(04)61603-3)
12 Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends in Endocrinology and Metabolism 2004 15 432–438. (doi:10.1016/S1043-2760(04)00214-0)
13 Wilson JD, Auchus RJ, Leiby MW, Guryev OL, Estabrook RW, Osborn SM, Shaw G & Renfree MB. Salpha-Androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving Salpha-pregnane-3alpha,17beta-diol-20-one as a key intermediate. Endocrinology 2003 144 575–580. (doi:10.1210/en.2002-220721)
14 Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ & Sharifi N. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. PNAS 2011 108 13728–13733. (doi:10.1073/pnas.1107898108)
15 Sharifi N & Auchus RJ. Steroid biosynthesis and prostate cancer. Steroids 2012 77 719–726. (doi:10.1016/j.steroids.2012.03.015)
16 Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C & Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clinical Chemistry 2003 49 1381–1395. (doi:10.1373/49.8.1381)
17 Labrie F. Intracrinology in action: importance of extragonadal 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. European Journal of Endocrinology/European Federation of Endocrine Societies 2016 174 601–609. (doi:10.1530/EJE-15-1181)
18 Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Storbeck KH, Bloem LM, Africander D, Schloms L & Swart AC. 11beta-Hydroxydihydrotestosterone and non-alcoholic fatty liver disease. Minerva Endocrinologica 2017 42 145–150. (doi:10.1530/EJE-16-0770)
19 Bloem LM, Storbeck KH, Swart P, du Toit T, Scholms L & Swart AC. Advances in the analytical methodologies: profiling steroids in familiar pathways-challenging dogmas. Journal of Steroid Biochemistry and Molecular Biology 2015 153 80–92. (doi:10.1016/j.jsbmb.2015.04.009)
20 Storbeck KH, Bloem LM, Africander D, Scholms L, Swart P & Swart AC. 11beta-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic
activity: a putative role in castration resistant prostate cancer? Molecular and Cellular Endocrinology 2013 377 135–146. (doi:10.1016/j.mce.2013.07.006)

21 Pretorius E, Africander DJ, Vlok M, Perkins MS, Quansoon J & Storbeck KH. 11-Ketotestosterone and 11-ketohydroxysterone in castration resistant prostate cancer: potent androgens which can no longer be ignored. PLoS ONE 2016 11 e0159867. (doi:10.1371/journal.pone.0159867)

22 O’Reilly MW, Kempegowda P, Jenkinson C, Taylor AE, Quansoon JL, Storbeck KH & Arlt W. 11-Oxynated C19 steroids are the predominant androgens in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2017 102 840–848. (doi:10.1210/jc.2016-2385)

23 Yildiz BO, Bodzag G, Yapiçi Z, Esiner I & Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Human Reproduction 2012 27 3067–3073. (doi:10.1093/humrep/des322)

24 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41–47. (doi:10.1093/humrep/deh098)

25 O’Reilly MW, Taylor AE, Crabtree NJ, Hughes BA, Capper F, Crowley RK, Stewart PM, Tomlinson JW & Arlt W. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. Journal of Clinical Endocrinology and Metabolism 2014 99 1027–1036. (doi:10.1210/jc.2013-3399)

26 Pasquali R, Zanotti L, Fanelli F, Mezzullo M, Fazzini A, Morselli Labate AM, Repaci A, Ribichini D & Gambineri A. Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective. Journal of Clinical Endocrinology and Metabolism 2016 101 2013–2022. (doi:10.1210/jc.2015-4009)

27 Munzker J, Hofer D, Trummer C, Ulbing M, Harger A, Pieber T, Pieber T, O’Reilly MW, Hughes BA, de Vries MC, Kant SG, Santen GW & Santen RW. 11-Ketotestosterone and 11-ketodihydrotestosterone accumulation in incubations of human ovarian stroma – in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations. Steroids 2016 11 177–184. (doi:10.1055/s-2016-749606)

28 Fassnacht M, Schlenz N, Schneider SB, Wady SA, Alloolio B & Arlt W. Beyond adrenal and ovarian androgen generation: increased peripheral S alpha-reductase activity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2015 100 653–660. (doi:10.1210/jc.2014-2523)

29 Stewart PM, Shackleton CH, Beastall GH & Edwards CR. Salpha-Reductase activity in polycystic ovary syndrome. Lancet 1990 335 431–433. (doi:10.1016/0140-6736(90)90664-Q)

30 Vassiliadis DA, Barber TM, Hughes BA, McCarthy MJ, Wiss JA, Franks S, Nightingale P, Tomlinson JW, Arlt W & Stewart PM. Increased S alpha-reductase activity and adenocortical drive in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2009 94 3558–3566. (doi:10.1210/jc.2009-0847)

31 Torchon LC, Idkowiak J, Fogel NR, O’Neill DM, Shackleton CH, Arlt W & Dunafay A. Evidence for increased Salpha-reductase activity during early childhood in daughters of women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2016 101 2069–2075. (doi:10.1210/jc.2015-3926)

32 Legro RS, Kunselman AR, Stetter CM, Gnatuk CL, Estes SJ, Brindle E, Vesper HW, Botelho JC, Lee PA & Dodson WC. Normal pubertal development in daughters of women with PCOS: a controlled study. Journal of Clinical Endocrinology and Metabolism 2017 102 122–131. (doi:10.1210/jc.2017-00867)

33 Sir-Petermann T, Codner E, Perez V, Echibusu B, Maliqueo M, Ladron de Guevara A, Preisler J, Crisostoto N, Sanchez F, Cassotta F et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. Gynecologic and Reproductive Science 2014 61 189–199. (doi:10.1007/s11873-013-0305-3)

34 Quinkler M, Sinha B, Tomlinson JW, Bujański JI, Stewart PM & Arlt W. Androgen generation in adipose tissue in women with simple obesity – a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. Journal of Endocrinology 2004 183 331–342. (doi:10.1677/joe.0.05762)

35 Wang L, Li S, Zhao A, Tao T, Mao X, Zhang P & Liu W. The expression of sex steroid synthesis and inactivation enzymes in subcutaneous adipose tissue of PCOS patients. Journal of Steroid Biochemistry and Molecular Biology 2012 132 120–126. (doi:10.1016/j.jsbmb.2012.02.003)

36 Pasquali R, Gambineri A, Cavazza C, Ibarra Gasparini D, Ciampaglia W, Cognigni GE & Patogotto U. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. European Journal of Endocrinology 2011 164 53–60. (doi:10.1530/EJE-10-0692)

37 Speiser PW & White PC. Congenital adrenal hyperplasia. New England Journal of Medicine 2003 349 776–788. (doi:10.1056/NEJMra021561)

38 Held PK, Shapira SK, Hinton CF, Jones E, Hannon WH & Ojodu J. Congenital adrenal hyperplasia cases identified by newborn screening in one- and two-screen states. Molecular Genetics and Metabolism 2015 116 133–138. (doi:10.1016/j.mgen.2015.08.004)

39 Trapp CM & Oberfield SE. Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update. Steroids 2012 77 342–346. (doi:10.1016/j.steroids.2011.12.009)

40 Speiser PW, Dupont B,Rubinstein P, Piazza A, Kastelan A & New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. American Journal of Human Genetics 1985 37 650–667.

41 Parsa AA & New MI. Steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia. Journal of Steroid Biochemistry and Molecular Biology 2017 165 2–11. (doi:10.1016/j.jsbmb.2016.06.015)

42 Pignatelli D. Non-classic adrenal hyperplasia due to the deficiency of 21-hydroxylase and its relation to polycystic ovarian syndrome. Frontiers of Hormone Research 2013 40 158–170. (doi:10.1016/j.jsteroids.2012.12.009)

43 Elhammar H & Nordenstrom A. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome. Endocrine 2015 50 32–50. (doi:10.1007/s12020-015-0656-0)

44 Moran C & Aziz R. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender. Seminars in Reproductive Medicine 2003 21 295–300. (doi:10.1055/s-2003-43307)

45 Noordam C, Dhur V, McNelis JC, Schlereh F, Hanley NA, Krone N, Smetting J, Smets EE, Sweep FC, Claasen-van den Grinten HL et al. Inactivating PAPSS2 mutations in a patient with premature pubarche. New England Journal of Medicine 2009 360 2310–2318. (doi:10.1056/NEJMoa0810489)

46 Mueller JW, Galligan LC, Idkowiak J, Arlt W & Foster PA. The regulation of steroid action by sulfation and desulfation. Endocrine Reviews 2015 36 526–563. (doi:10.1210/er.2015-1036)

47 Oostdijk W, Idkowiak J, Mueller JW, House PJ, Taylor AE, O’Reilly MW, Hughes BA, de Vries MC, Kant SG, Santen GW et al. PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation – in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations. Journal of Clinical Endocrinology and Metabolism 2015 100 657–668. (doi:10.1210/jc.2014-3556)

48 Semple RK, Savage DB, Cochran EK, Gordon P & O’Rahilly S. Genetic syndromes of severe insulin resistance. Endocrine Reviews 2011 32 498–514. (doi:10.1210/er.2010-0020)
and theca. Obstetrics and Gynecology 1984 64 73s–80s. (doi:10.1097/00006250-19840901-00019)

50 Jones TH. Testosterone associations with erectile dysfunction, diabetes, and the metabolic syndrome. European Urology Supplements 2007 6 847–857. (doi:10.1016/j.eursup.2007.07.002)

51 Ahern T, Swiecicka A, Eendebak RJ, Carter EL, Finn JD, Pye SR, O’Neill TW, Antonio L, Keevil B, Bartfai G et al. Natural history, risk factors and clinical features of primary hypogonadism in ageing men: Longitudinal Data from the European Male Ageing Study. Clinical Endocrinology 2016 85 891–901. (doi:10.1111/cen.13152)

52 Rey RA & Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Practice and Research Clinical Endocrinology and Metabolism 2011 25 221–238. (doi:10.1016/j.beem.2010.08.013)

53 Bastida MG, Rey RA, Bergada I, Bedefarca P, Andreu E, del Rey G, Boywittr A, Ropelato MG, Cassinelli H, Arcari A et al. Establishment of testicular endocrine function impairment during childhood and puberty in boys with Klenefelter syndrome. Clinical Endocrinology 2007 67 863–870. (doi:10.1111/j.1365-2265.2007.02977.x)

54 Lanfranco F, Kaminichek A, Zitzmann M & Nieschlag E. Klinefelter’s syndrome. Lancet 2004 364 273–283. (doi:10.1016/S0140-6736(04)6678-6)

55 Boehm U, Bouloum PM, Dattani MT, de Roux N, Dode C, Dunkel I, Dwyer AA, Giacobini P, Hardelin JF, Juul A et al. Expert consensus document: European Consensus Statement on congenital hypogonadotrophic hypogonadism – pathogenesis, diagnosis and treatment. Nature Reviews Endocrinology 2015 11 547–564.

56 Golabeck T, Belsky J, Drewa T, Koldziej A, Skoneczna I, Milecki P, Drabuch J, Slojeswki M & Chlota PL. Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer. Central European Journal of Urology 2016 69 131–138. (doi:10.1016/euroj.2015.11.031)

57 Schubert M & Jockenhovel F. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects. Journal of Endocrinological Investigation 2005 28 23–27. (doi:10.1007/BF03434525)

58 Beattie MC, Adedokola L, Papadopoulos Y, Chen H & Zirkin BR. Leydig cell aging and hypogonadism. Experimental Gerontology 2015 68 87–91. (doi:10.1016/j.exger.2015.02.014)

59 Golan R, Scovell JM & Ramasamy R. Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male 2015 18 201–204. (doi:10.3109/136883538.2015.1052392)

60 Camacho EM, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, Tajar A, Bartfai G, Boonen S, Casanueva FF et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. European Journal of Endocrinology 2013 168 445–455. (doi:10.1530/EJE-12-0890)

61 Corona G, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G, Bandini E, Forti G & Maggi M. Low levels of androgens in men with erectile dysfunction and obesity. Journal of Sexual Medicine 2008 5 2454–2463. (doi:10.1111/j.1743-6609.2008.00856.x)

62 Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, Facchiano E, Sforza A, Forti G, Mannucci E et al. Body weight loss reverts obesity-associated hypogonadotrophic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology 2013 168 829–845. (doi:10.1530/EJE-12-0915)

63 Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt – a major factor in the genesis of morbid obesity. Medical Hypotheses 1999 52 49–51. (doi:10.1054/mehy.1999.0624)

64 Kelly DM & Jones TH. Testosterone and obesity. Obesity Reviews 2015 16 581–606. (doi:10.1111/obr.12282)

65 Pitteloud N, Dwyer AA, De Cruz S, Lee H, Boeppe PA, Crowley WF Jr & Hayes FJ. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. Journal of Clinical Endocrinology and Metabolism 2008 93 784–791. (doi:10.1210/jc.2007-2156)

66 de Boer H, Verschoor L, Ruinemans-Koerts J & Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes, Obesity and Metabolism 2005 7 211–215. (doi:10.1111/j.1462-2607.2004.00097.x)

67 van der Poll T, Romijn JA, Endert E & Sauerwein HP. Effects of tumor necrosis factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism 1993 42 303–307. (doi:10.1016/0026-0495(93)90078-3)

68 Veldhuis J, Yang R, Roelfsema F & Takahashi P. Proinflammatory cytokine infusion augments Ih’s feedforward on testosterone secretion: modulation by age. Journal of Clinical Endocrinology and Metabolism 2016 101 539–549. (doi:10.1210/jc.2015-3611)

69 Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A & Fabbri A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. Journal of Clinical Endocrinology and Metabolism 1999 84 3673–3680. (doi:10.1210/jc.84.10.3673)

70 Hembree WC, Cohen-Kettenis P, Delemarre-van De Waal HA, Gooren LJ, Meyer WF 3rd, Spack NP, Tangpricha V & Montori VM. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2009 94 3132–3154. (doi:10.1210/jc.2009-0345)

71 Unger CA. Hormone therapy for transgender patients. Translational Andrology and Urology 2016 5 877–884. (doi:10.21037/tau.2016.09.04)

72 Gooren LJ & Giltay EJ. Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects. Andrologia 2014 46 570–575. (doi:10.1111/and.12111)

73 Auer MK, Cecil A, Roepke Y, Bultynck C, Pas C, Fuss J, Prehn C, Wang-Sattler R, Adamski J, Stalla GK et al. 12-Months metabolic changes among gender dysphoric individuals under cross-sex hormone treatment: a targeted metabolomics study. Scientific Reports 2016 6 37005. (doi:10.1038/srep37005)

74 Elbers JM, Asscheman H, Seidell JC & Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. American Journal of Physiology 1999 276 E317–E325.

75 Deutsch MB, Bhakri V & Kubicki K. Effects of cross-sex hormone treatment on transgender women and men. Obstetrics and Gynecology 2015 125 605–610. (doi:10.1097/AOG.0000000000000692)

76 Fernandez JD & Tannock LR. Metabolic effects of hormone therapy in transgender patients. Endocrine Practice 2016 22 383–388. (doi:10.4158/EP15950.0R)

77 Eln M, Adachi M, Sasaki A, Nakamura Y & Nakatsuka M. Increased arterial stiffness in female-to-male transsexuals treated with androgen. Journal of Obstetrics and Gynaecology Research 2008 34 890–897. (doi:10.1111/j.1447-0756.2008.00857.x)

78 Elamin MB, Garcia MZ, Murad MH, Erwin PJ & Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clinical Endocrinology 2010 72 1–10. (doi:10.1111/j.1365-2265.2009.03632.x)

79 Wierckx K, Elaut E, Declercq A, Heylens G, De Cuyper G, Tae Y, Kaufman JM & T’Sjoen G. Prevalence of cardiovascular
Androgens in metabolic disease

Rebuffe-Scrive M, Marin P & Bjornorp P. Effect of testosterone on abdominal adipose tissue in men. International Journal of Obesity 1991 15 791–795.

Dicker A, Ryden M, Naslund E, Muehlen IE, Wiren M, Lafontan M & Arner P. Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia 2004 47 420–428. (doi:10.1007/s00125-003-1324-0)

Belanger C, Houde P, Lefebre S, Bärt SAN & Tchernoff A. Omental and subcutaneous adipose tissue steroid levels in obese men. Steroids 2006 71 674–682. (doi:10.1016/j.steroids.2006.04.008)

Hernandez-Morante JJ, Perez-de-Heredia F, Lujan JA, Zamora S & Garaulet M. Role of DHEA-S on body fat distribution: gender- and depot-specific stimulation of adipose tissue lipolysis. Steroids 2008 73 209–215. (doi:10.1016/j.steroids.2007.10.005)

Corton M, Botella-Carretero JJ, BENGURIA A, Villuendas G, ZABALLOS A, San Millan JL, Escobar-Morreale HF & Perez B. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 328–337. (doi:10.1210/jc.2006-1665)

Corton M, Botella-Carretero JJ, Lopez JA, Camaferta E, San Millan JL, Escobar-Morreale HF & Perez B. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Human Reproduction 2008 23 651–661. (doi:10.1093/humrep/dem380)

Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. Journal of Endocrinology 2007 192 585–594. (doi:10.1677/joe.1.07070)

Kelly DM & Jones TH. Testosterone: a metabolic hormone in health and disease. Journal of Endocrinology 2013 217 R25–R45. (doi:10.1530/JOE-12-0455)

Kadi F, Eriksson A, Holmner S & Thornell LE. Effects of anabolic steroids on the muscle cells of strength-trained athletes. Medicine and Science in Sports and Exercise 1999 31 1528–1534. (doi:10.1097/00005768.19991100.00006)

Sinha-Hikim I, Cornoalex M, Gaytan H, Lee ML & Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. Journal of Clinical Endocrinology and Metabolism 2006 91 3024–3033. (doi:10.1210/jc.2006-0357)

Singh R, ARTAZA JN, Taylor WE, Gonzalez-Cadavid NF & Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Journal of Physiology: Endocrinology and Metabolism 2010 134 277–284. (doi:10.1016/j.jsbm.2014.04.008)

Chazbenalk G, Singh P, Igre D, Shah A, Abbott DH & Dumesic ORE. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids 2013 78 920–926. (doi:10.1016/j.steroids.2013.05.001)

Blouin K, Nadeau M, Perreault M, Veilleux A, Drouet R, Marceau P, Mailloux J, Luu-The V & Tchernoff A. Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clinical Endocrinology 2010 72 176–188. (doi:10.1111/j.1365-2265.2009.03645.x)

McNels JC, Manolopoulous KN, Gathercole LL, Bujalska JI, Stewart PM, Tomlinson JW & Artt W. Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake. American Journal of Physiology: Endocrinology and Metabolism 2013 305 E1134–E1144. (doi:10.1152/ajpendo.00314.2012)

Kloeting N & Bluher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Reviews in Endocrine and Metabolic Disorders 2014 15 277–287. (doi:10.1007/s11154-014-9301-0)

Toulis KA, Goulis DG, Mintziorti G, Kintiraki K, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergiouos S, Poulasouchidou M, Zellos TG et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Human Reproduction Update 2011 17 741–760. (doi:10.1093/humupd/dmr025)

Lafranco E, Zitzmann M, Simon M & Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clinical Endocrinology 2004 60 500–507. (doi:10.1111/j.1365-2265.2004.02807.x)

Elbers JM, de Jong S, Teerlink T, Asscheman H, Soeldell JC & Gooren LJ. Changes in fat cell size and in vitro lipolytic activity of abdominal and gluteal adipocytes after a one-year cross-sex hormone administration in transsexuals. Metabolism 1999 48 1371–1377. (doi:10.1016/S0026-0495(99)00146-4)
109 Usui T, Kajita K, Kajita T, Mori I, Hanamot T, Ikeda T, Okada H, Taguchi K, Kitada Y, Morita H et al. Elevated mitochondrial biogenesis in skeletal muscle is associated with testosterone-induced body weight loss in male mice. FEBS Letters 2014 588 1935–1941. (doi:10.1016/j.febslet.2014.03.051)

110 Salehzadeh F, Rune A, Olsen M & Al-Khallali L. Testosterone or 17[beta]-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes. Journal of Endocrinology 2011 210 219–229. (doi:10.1530/JOE-10-0497)

111 Sato K, Iemitsu M, Aizawa K & Ajiyas R. Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle. American Journal of Physiology: Endocrinology and Metabolism 2008 294 E961–E968. (doi:10.1152/ajpendo.00678.2007)

112 Bergamini E, Bombara G & Pellegrino C. The effect of testosterone on glycogen metabolism in rat levator ani muscle. Biochimica et Biophysica Acta (BBA): General Subjects 1969 177 220–234. (doi:10.1016/0304-4165(69)90131-7)

113 Bergamini E. Different mechanisms in testosterone action on glycogen metabolism in rat perirenal and skeletal muscles. Endocrinology 1975 96 77–84. (doi:10.1210/end-96-1-77)

114 Consensus Development Conference on Insulin Resistance. 5–6 November 1997. American Diabetes Association. Diabetes Care 1998 21 310–314. (doi:10.2337/diabetes.21.2.310)

115 Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK & Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999 22 141–146. (doi:10.2337/diabetes.22.2.141)

116 Legro RS, Kunselman AR, Dodson WC & Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology and Metabolism 1999 84 165–169. (doi:10.1210/00000188-19990600-00009)

117 Dunaif A, Segal KR, Futterweit W & Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989 38 1165–1174. (doi:10.2337/ dbi.38.9.1165)

118 Ding EL, Song Y, Malik VS & Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006 295 1288–1299. (doi:10.1001/jama.295.11.1288)

119 Banaszewska B, Wrotniak-Barczynska J, Spaczynski RZ, Pawelczyk I & Duleba AJ. Effects of resveratrol on polycystic ovary syndrome: prospective cohort study. Human Reproduction 2012 153 4019–4029. (doi:10.1210/jc.2012-1385)

120 Ortega I, Villanueva JA, Wong DH, Cress AB, Sokalska A, Stanley PD & Duleba AJ. Resveratrol reduces steroidogenesis in rat ovarian theca-interstitial cells: the role of inhibition of Akt/PKB signaling pathway. Endocrinology 2012 153 4019–4029. (doi:10.1210/jc.2012-1385)

121 Blouin K, Despres JP, Couillard C, Tremblay A, Prud’homme D, Bouchard C & Tchernof A. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 2005 54 1034–1040. (doi:10.1016/j.metabol.2005.03.006)

122 Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, Zajac JD & Jerums G. Low testosterone levels are common and associated with insulin resistance in men with diabetes. Journal of Clinical Endocrinology and Metabolism 2008 93 1834–1840. (doi:10.1210/jc.2007-2177)

123 Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R & Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004 27 1036–1041. (doi:10.2337/diacare.27.5.1036)

124 Li C, Ford ES, Li B, Giles WH & Liu S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care 2010 33 1618–1624. (doi:10.2337/dc09-1788)

125 Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, Chaudhuri A & Dandona P. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010 33 1186–1192. (doi:10.2337/dc09-1649)

126 Basaria S, Muller DC, Carducci MA, Egan J & Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006 106 581–588. (doi:10.1002/cncr.21642)

127 Kapoor D, Goodwin E, Chanter KS & Jones TH. Testosterone replacement therapy improves insulin resistance, glycemic control, visceral adiposity and hyperglycemia in men with type 2 diabetes. European Journal of Endocrinology 2006 154 899–906. (doi:10.1530/eje.1.02166)

128 Haider A, Yassin A, Doros G & Saad F. Effects of long-term testosterone therapy on patients with ‘diabetes’: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. International Journal of Endocrinology 2014 2014 683515.

129 Barber TM, Golding SJ, Alvey C, Wess JA, Karpe F, Franks S & McCarthy MI. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008 93 999–1004. (doi:10.1210/jc.2007-2117)

130 Borrue S, Fernandez-Duranz E, Alpanes M, Marti D, Alvarez-Blasco F, Luque-Ramirez M & Esclarob-Morreb HE. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). Journal of Clinical Endocrinology and Metabolism 2013 98 1254–1263. (doi:10.1210/jc.2012-3698)

131 Ezeu U, Pall M, Mathur R & Aziz R. Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome. Human Reproduction 2014 29 1508–1517. (doi:10.1093/humrep/deu996)

132 Kirchengart S & Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Human Reproduction 2001 16 1255–1260. (doi:10.1093/humrep/16.6.1255)

133 Valderhaug TG, Hertel JK, Nordstrand N, Dale PO, Hofso D & Hjelmesaeth J. The association between hyperandrogenemia and the metabolic syndrome in morbidly obese women. Diabetes and Metabolic Syndrome 2015 7 46. (doi:10.1016/s1399-0150-0040-5)

134 Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M & Pigny F. Oligoovulation with polycystic ovaries but not overt hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 2006 91 3922–3927. (doi:10.1210/jc.2006-0354)

135 Dinhaz B, Orzkaya E, Cinar M, Cakir E & Dinhaz S. Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 2011 39 272–277. (doi:10.1007/s12020-011-9437-6)

136 Ollila MM, Pilttson T, Puukka K, Tuokkonen A, Jarvelin MR, Tapanainen JS, Franks S & Morin-Papunen L. Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome: prospective cohort study. Journal of Clinical Endocrinology and Metabolism 2016 101 739–747. (doi:10.1210/jc.2015-3345)

137 Kim SH, Moon JY, Sasano H, Choi MH & Park MJ. Body fat mass is associated with ratio of steroid metabolites reflecting 17,20-lyase activity in prepubertal girls. Journal of Clinical Endocrinology and Metabolism 2016 101 4653–4660. (doi:10.1210/jc.2016-2515)
of non-invasive indices predicting hepatic steatosis and fibrosis. *Hormones* 2014 13 519–531.

152 Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. *Journal of Clinical Endocrinology and Metabolism* 2012 97 3709–3716. (doi:10.1210/jc.2012-1382)

153 Palioura E, Palmeri S, Pipera C, Sakellariou S, Kandarakis E, Sergentanis T, Levidou G, Agrogiannis G, Papalois A, Korkolopoulou P et al. Impact of androgen and dietary advanced glycation end products on female rat liver. *Cellular Physiology and Biochemistry* 2015 37 1134–1146. (doi:10.1007/s40618-016-0480-2)

154 Kim S, Kwon H, Park JH, Cho B, Kim D, Oh SW, Lee CM & Choi HC. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. *BMC Gastroenterology* 2012 12 69. (doi:10.1186/1471-230X-12-69)

155 Volzke H, Aumann N, Krebs A, Nauck M, Steveling A, Len MCH, Rosskopf D & Wallaschfski H. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. *International Journal of Andrology* 2010 33 45–53. (doi:10.1111/j.1466-2916.2009.00953.x)

156 Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuawirji S, Hsu CL, Ma WL, Jokinen J, Sparks JD et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. *Hepatology* 2008 47 1924–1935.

157 Schwingel PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, Andrade AR & Zoppo CC. Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. *Liver International* 2011 31 348–353. (doi:10.1111/j.1478-3231.2010.02346.x)

158 Yang Y, Yang S, Li R, Liu P, Qiao J & Zhang Y. Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis. *Reproductive Biology and Endocrinology* 2016 14 67. (doi:10.1186/s12958-016-0203-8)

159 Diamantini-Kandarakis E, Mittrakou A, Raptis S, Tolis G & Duleba AJ. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. *Journal of Clinical Endocrinology and Metabolism* 1998 83 2699–2705. (doi:10.1210/jcem.83.5.8041)

160 Murri M, Luque-Ramirez M, Insenser M, Ferrer MC & Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. *Human Reproduction Update* 2013 19 268–288. (doi:10.1093/humupd/dms059)

161 Meng Y, Chen X, Peng Z, Liu X, Sun Y & Dai S. Association between high serum homocysteine levels and biochemical characteristics in women with polycystic ovarian syndrome: a systematic review and meta-analysis. *PLoS ONE* 2016 11 e0157389. (doi:10.1371/journal.pone.0157389)

162 Peng Z, Sun Y, Lv X, Zhang H, Liu C & Dai S. Interleukin-6 levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. *PLoS ONE* 2016 11 e0148531. (doi:10.1371/journal.pone.0148531)

163 Gao L, Gu Y & Yin X. High serum tumor necrosis factor-alpha levels in women with polycystic ovary syndrome: a meta-analysis. *PLoS ONE* 2016 11 e0164021. (doi:10.1371/journal.pone.0164021)

164 Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F & Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. *Human Reproduction* 2007 22 3197–3203. (doi:10.1093/humrep/dem324)

165 Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H & Connell JM. Altered vascular function in young women with polycystic ovary
syndrome. *Journal of Clinical Endocrinology and Metabolism* 2002 **87** 742–746. (doi:10.1210/jcem.87.2.81999)

166  Paradisi G, Steinberg HO, Hempling A, Cronin J, Hook G, Shepard MK & Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. *Circulation* 2001 **103** 1410–1415. (doi:10.1161/01.CIR.103.10.1410)

167  Morgan CL, Jenkins-Jones S, Currie CJ & Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. *Journal of Clinical Endocrinology and Metabolism* 2012 **97** 3251–3260. (doi:10.1210/jc.2012-1690)

168  Chang AV, Ayers C, Minhaajuddin A, Jain T, Nurenberg P, de Lemos JA, Wild RA & Achaus RJ. Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. *Clinical Endocrinology* 2011 **74** 89–96. (doi:10.1111/j.1365-2125.2010.03907.x)

169  Itikhar S, Collazo-Clavell ML, Roger VL, St Sauver J, Brown RD Jr, Cha S & Rhodes DJ. Risk of cardiovascular events in patients with polycystic ovary syndrome. *Netherlands Journal of Medicine* 2012 **70** 74–80.

170  Schmidt J, Landin-Wilhelmsen K, Brannstrom M & Dahlgren L. Schiffer and others Androgens in metabolic disease

www.eje-online.org

Review

L. Schiffer and others

Androgens in metabolic disease

173  de Groot PC, Dekkers OM, Romijn JA, Dieben SW & Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. *Human Reproduction Update* 2011 **17** 495–500. (doi:10.1093/humupd/dmt001)

174  Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH & Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. *Journal of Clinical Epidemiology* 1998 **51** 581–586. (doi:10.1016/S0895-4356(98)00035-3)

175  Wu FC & von Eckardstein A. Androgens and coronary artery disease. *Endocrine Reviews* 2003 **24** 183–217. (doi:10.1210/01.ER.2001-0025)

176  Barrett-Connor E & Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. *Circulation* 1978 **58** 539–545. (doi:10.1161/01.CIR.78.3.539)

177  Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. *Annals of Internal Medicine* 1992 **117** 807–811. (doi:10.7326/0003-4819-117-10.807)

178  Haffner SM, Mykkkanen I, Valdez RA & Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. *Journal of Clinical Endocrinology and Metabolism* 1993 **77** 1610–1615.

179  Simon D, Charles MA, Nahouli K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L & Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. *Journal of Clinical Endocrinology and Metabolism* 1997 **82** 682–685.

180  Barud W, Palusinski R, Beltowski J & Wojcicka G. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. *Atherosclerosis* 2002 **164** 283–288. (doi:10.1016/S0002-9150(02)00069-2)

181  Smith MR, Lee H & Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. *Journal of Clinical Endocrinology and Metabolism* 2006 **91** 1305–1308. (doi:10.1210/jc.2005-2507)

182  Nishiyama T, Ishizaki F, Anraku T, Shimura H & Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. *Journal of Clinical Endocrinology and Metabolism* 2005 **90** 657–660. (doi:10.1210/jc.2004-1611)

183  Braga-Basaria M, Muller DC, Carducci MA, Dobs AS & Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. *International Journal of Impotence Research* 2006 **18** 494–498. (doi:10.1086/si.jir.3901471)

184  Malkin C, Pugh PJ, Jones RD, Kapoor D, Channer KS & Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. *Journal of Clinical Endocrinology and Metabolism* 2004 **89** 3313–3318. (doi:10.1210/jc.2003-031069)

185  Janjigava S, Zerekidze T, Uchava L, Giorgadze E & Asatiani K. Influence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency. *European Journal of Medical Research* 2014 **19** 56. (doi:10.1186/s40001-014-0056-6)

186  Kaplan SA, Johnson-Levonas AO, Lin J, Shah AK & Meehan HA. Elevated high sensitivity C-reactive protein levels in aging men with low testosterone. *Aging Male* 2010 **13** 108–112. (doi:10.3109/13655530903440424)

187  Naifar M, Rekik N, Messedi M, Chaabouni A, Turki M, Abid M, Ayedi F & Jamousi K. Male hypogonadism and metabolic syndrome. *Andrologia* 2015 **47** 579–586. (doi:10.1111/and.12055)

188  Kalinchenko SY, Tishova YA, Mskhalya GJ, Gooren LJG, Giltay EJ & Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. *Clinical Endocrinology* 2010 **73** 602–612. (doi:10.1111/j.1365-2265.2010.03845.x)

189  Yaron M, Greenman Y, Rosenfeld JB, Izhkavk E, Limor R, Osher E, Shenkerman G, Tordjman K & Stern N. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. *European Journal of Endocrinology* 2009 **160** 839–846. (doi:10.1530/EJE-09-0052)

190  Rosano GM, Sheikh I, Massaro P, Pagnotta P, Marazzi G, Vitale C, Mercuro G, Vollandt M, Aversa A & Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina. *International Journal of Impotence Research* 2007 **19** 176–182. (doi:10.1350/ijir.2007.01504)

191  English KM, Mandour O, Steeds RP, Diver MJ, Jones TH & Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. *European Heart Journal* 2000 **21** 890–894. (doi:10.1053/euhj.1999.1873)

192  Hu X, Rui L, Zhu T, Xia H, Yang X, Wang X, Liu H, Lu Z & Jiang H. Low testosterone level in middle-aged male patients with coronary artery disease. *European Journal of Internal Medicine* 2011 **22** e133–e136. (doi:10.1016/j.ejim.2011.08.014)

193  Li L, Guo CY, Jia EZ, Zhu TB, Wang LS, Cao KJ, Ma WZ & Yang ZJ. Testosterone is negatively associated with the severity of coronary atherosclerosis in men. *Asian Journal of Andrology* 2012 **14** 875–878. (doi:10.1388/ajaj.2012.95)

194  Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SA & Yeap BB. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. *Journal of Clinical Endocrinology and Metabolism* 2012 **97** 179–189. (doi:10.1210/jc.2011-1617)

195  Pye SR, Hultstrom TF, Finn JD, Lee DM, O'Neill TW, Tajar A, Bartfai G, Boonen S, Casanueva FF, Forti G et al. Late-onset hypogonadism and mortality in aging men. *Journal of Clinical Endocrinology and Metabolism* 2014 **99** 1357–1366. (doi:10.1210/jc.2013-2052)

196  Khaw KT, Dowsett M, Folkert E, Bingham S, Wareham N, Luben R, Welch A & Day N. Endogenous testosterone and mortality due
to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007 116 2694–2701. (doi:10.1161/CIRCULATIONAHA.107.719005)

197 O’Reilly MW, Reulen RC, Gupta S, Thompson CA, Dineen R, Goulden EL, Bugg G, Pearce H, Toogood AA, Gittoes NJ et al. ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: long-term follow-up of 519 patients in two large European centres. Clinical Endocrinology 2016 85 748–756.

198 Anderson JL, May HT, Lappe DL, Bair T, Le V, Carlquist JF & Muhlestein JB. Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system. American Journal of Cardiology 2016 117 794–799. (doi:10.1016/j.amjcard.2015.11.063)

199 Shores MM, Smith NL, Forsberg CW, Anawalt BD & Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. Journal of Clinical Endocrinology and Metabolism 2012 97 2050–2058. (doi:10.1210/jc.2011-2591)

200 Bui HN, Sluss PM, Hayes JF, Blincko S, Knol DL, Blankenstein MA & Heijboer AC. Testosterone, free testosterone, and free androgen index in women: reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. Clinica Chimica Acta 2015 450 227–232. (doi:10.1016/j.cca.2015.08.019)

201 Arlt W, Willis DS, Wild SH, Krone N, Doherty Ej, Hahner S, Han TS, Carroll PV, Conway GS, Rees DA et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. Journal of Clinical Endocrinology and Metabolism 2010 95 5110–5121. (doi:10.1210/jc.2010-0917)

202 Damgaard-Olesen A, Johanssen TH, Holmboe SA, Soeborg T, Petersen JH, Andersson A, Aadahl M, Linneberg A & Juul A. Reference ranges of 17-hydroxyprogesterone, DHEA, DHEAS, androstenedione, and total free testosterone determined by TurboFlow-LC-MS/MS and associations to health markers in 304 men. Clinica Chimica Acta 2016 454 82–88. (doi:10.1016/j.cca.2015.12.042)

203 Belli S, Santi D, Leoni E, Dall'Olio E, Fanelli F, Mezzullo M, Pelusi C, Roli L, Tagliavini S, Trenti T et al. Human chonic gonadotropin stimulation gives evidence of differences in testicular steroidogenesis in Klinefelter syndrome, as assessed by liquid chromatography-tandem mass spectrometry. European Journal of Endocrinology 2016 174 801–811. (doi:10.1530/EJE-15-1224)

204 Giton F, Trabado S, Malone J, Sarafat J, Le Bouc Y, Braillly-Tabard S, Fiet J & Younig J. Sex steroids, precursors, and metabolite deficiencies in men with isolated hypogonadotrophic hypogonadism and panhypopituitarism: a GCMS-based comparative study. Journal of Clinical Endocrinology and Metabolism 2015 100 E292–E296. (doi:10.1210/jc.2014-2658)

205 Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S & Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine 2004 83 209–222. (doi:10.1097/01.md.0000136265.73570.54)

206 Elbers JM, Giltay Ej, Teerling T, Scheffer PG, Asscheman H, Seidell JC & Gooren LJ. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clinical Endocrinology 2003 58 562–571. (doi:10.1046/j.1365-2265.2003.01753.x)

207 Selvin E, Feinleib M, Zhang L, Rohrmann S, Riffai N, Nelson WG, Dobs A, Basaria S, Golden SH & Platz EA. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007 30 234–238. (doi:10.2337/dc06-1579)

208 Barbonetti A, Caterina Vassallo MR, Cotugno M, Felzani G, Francavilla S & Francavilla F. Low testosterone and non-alcoholic fatty liver disease: Evidence for their independent association in men with chronic spinal cord injury. Journal of Spinal Cord Medicine 2016 39 443–449.

209 Traish AM, Haider A, Doros G & Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. International Journal of Clinical Practice 2014 68 314–329. (doi:10.1111/ijcp.12319)

Received 13 February 2017
Revised version received 12 April 2017
Accepted 3 May 2017